Alopecia Areata- Oral Medication
We know these are challenging times and venturing out can be especially stressful. We want you to know that at CRCC we have implemented every safety measure possible to keep you safe and prevent the spread of Covid-19. Patient areas are continually disinfected, social distancing is enforced in our lobby, and all staff wear masks/gloves throughout the day. If you arrive for your appointment and wish to wear a mask, we will provide one for you as well.
About Alopecia Areata
Sudden hair loss, starting with one or more circular bald patches that may overlap. Alopecia areata occurs when the immune system attacks hair follicles and may be brought on by severe stress. The main symptom is hair loss.
About the Studies
This study is testing an oral investigational medication that is taken twice a day. For the first 24 weeks, all patients will receive either 8mg twice daily or 12mg twice daily of study medication. After week 24 the dose of study medication will either be reduced to 8mg or to a placebo (sugar) neither the research center nor the patient will know what they are taking.
What to Expect
- Active drug for 24 weeks followed by reduced dose or placebo for up to 56 weeks.
Patients that complete this 80-week trial will have the opportunity to go into the open-label extension, where everyone is guaranteed active medication.
- Compensation may be available for time & travel.
If you are interested in participating in one of these studies please complete the form below and we will be in touch with you soon.
Your information will be used for the sole purpose of qualifying you for this study. We will not, in any circumstances, share your personal information with other individuals or organizations without your permission.